[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Sunnybrook Health Sciences Centre\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":652},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,115,0,25,[9,43,64,87,114,134,163,190,210,230,257,278,301,335,366,391,419,445,469,500,527,551,572,606,629],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100629600","csf-and-blood-plasma-liquid-biopsy-in-patients-with-metastatic-solid-tumours-and-cns-metastases-or-no-cns-metastases-100629600",false,"NCT07476781","CSF and Blood Plasma Liquid Biopsy in Patients With Metastatic Solid Tumours and CNS Metastases or no CNS Metastases","Exploring the Feasibility of Cerebrospinal Fluid (CSF) Liquid Biopsy in Patients With Metastatic Solid Tumours and Leptomeningeal Disease (Cohort A), Parenchymal Brain Metastases (Cohort B), or No Evidence of Central Nervous System (CNS) Metastases (Cohort C): A Pilot Study","Inclusion Criteria:\n\n* Diagnosed with a metastatic solid tumour in one of the following scenarios:\n\n  1. Patients in Cohort A will have previously untreated or progressing leptomeningeal metastatic disease (LMD) with or without parenchymal brain metastases (BrM).\n  2. Patients in Cohort B will have previously untreated or BrM but no evidence of LMD.\n  3. Patients in Cohort C will have progressing extra-cranial metastatic disease with no LMD or BrM.\n* Patient is suitable for lumbar puncture and\u002For has an Ommaya reservoir that is accessible for CSF collection.\n* Patient is eligible at any time point in their treatment course, including whether or not they have already started treatment for LMD. Considering the poor prognosis associated with LMD, rapid clinical deterioration, and the fact that available local and systemic therapies have not been shown to completely eradicate LMD, there is a high likelihood of detecting CSF biomarkers regardless of the timing of assessment. This flexible enrollment strategy is particularly important to support feasibility and recruitment in this less common and clinically challenging population. However, efforts will be made to collect CSF samples prior to treatment initiation and\u002For at the time of disease progression whenever possible.\n* Patients with active brain metastases, defined as newly diagnosed and previously untreated lesions, or lesions that were previously treated and are now progressing.\n* Patients who were previously enrolled in the study and had negative CSF biomarkers may be re-enrolled at a later time point (e.g., upon progression of CNS disease).\n\nExclusion Criteria:\n\n* Inability to understand or unwillingness to provide written informed consent (language barriers are not exclusionary; the use of a translator is permitted).\n* Patients with contraindications to lumbar puncture (e.g., infection at the LP site, uncontrolled bleeding diathesis \\> 1.5\\], severe thrombocytopenia \\[platelet count \\\u003C40,000\u002FµL\\], use of anticoagulant or antiplatelet medications cannot be safely interrupted, significant mass effect with risk of herniation, or presence of vertebral hardware)","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a prospective, single-centre feasibility study of CSF ctDNA conducted at the Sunnybrook Odette Cancer Centre (SOCC), Toronto, Canada, including multiple solid tumor, stratified into cohorts according to CNS disease involvement, including leptomeningeal disease (Cohort A), parenchymal brain metastases (Cohort B), and no evidence of CNS metastases (Cohort C).",[27,28,29],"Solid Tumor Malignancies","Brain Metastasases","Leptomeningeal Disease (LMD)","RECRUITING","2026-06-23",{"date":33,"type":34},"2026-06-26","ACTUAL",{"date":36,"type":34},"2025-12-12",{"date":38,"type":21},"2026-12",{"name":40,"class":41},"Sunnybrook Health Sciences Centre","OTHER",1,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":42},"100616667","evaluation-of-intercostal-neuralgia-in-patients-with-chest-tube-insertion-after-traumatic-rib-fracture-100616667","NCT07308587","Evaluation of Intercostal Neuralgia in Patients With Chest Tube Insertion After Traumatic Rib Fracture","Prospective Evaluation of Intercostal Neuralgia Incidence, Risk Factors, and Outcomes in Patients With Chest Tube Insertion After Traumatic Rib Fractures","Inclusion Criteria:\n\n* Adults (≥18 years) with traumatic rib fractures requiring chest tube insertion\n* Chest tube or pigtail insertion performed during their initial hospitalization for trauma\n\nExclusion Criteria:\n\n* Patients with spinal cord injury\n* Inability to complete follow-up assessments (e.g., language barriers, lack of telephone access)\n\nExclusion Criteria:\n\n* Patients with traumatic brain injury\n* Patients with spinal cord injury\n* Inability to complete follow-up assessments (e.g., language barriers, lack of telephone access)",{"count":51,"type":21},100,"OBSERVATIONAL","Traumatic rib fractures are common injuries following blunt chest trauma, often requiring chest tube insertion to manage complications such as pneumothorax or haemothorax. However, chest tube placement can lead to intercostal nerve injury, resulting in intercostal neuralgia-a debilitating condition characterized by chronic, neuropathic pain along the intercostal nerves. Despite its clinical significance, the incidence, risk factors, and long-term outcomes of intercostal neuralgia in this patient population remain poorly understood.\n\nChronic pain following thoracic trauma, including intercostal neuralgia, has been shown to significantly impair quality of life and functional outcomes, leading to prolonged disability and increased healthcare utilization. Current literature highlights the need for better understanding and management of this condition, particularly in patients undergoing invasive procedures such as chest tube insertion. This study aims to prospectively evaluate the development of intercostal neuralgia in patients with chest tube insertion following traumatic rib fractures.",[55],"Intercostal Nerve Injury","2026-05-13",{"date":58,"type":34},"2026-05-15",{"date":60,"type":34},"2026-01-19",{"date":62,"type":21},"2027-12-31",{"name":40,"class":41},{"id":65,"slug":66,"hasResults":12,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":12,"sex":72,"minAge":18,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":22,"phases":75,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":81,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":42},"100529693","pilot-study-of-dose-escalation-in-prostate-radiotherapy-using-the-mr-linac-destination-mrl-100529693","NCT06177093","Pilot Study of Dose Escalation in Prostate Radiotherapy Using the MR-Linac (DESTINATION-MRL)","A Pilot Study of Dose dE-eScalaTion IN prostATe radIOtherapy usiNg the MRL","DESTINATION-MR","Inclusion Criteria:\n\n* Men aged ≥18 years\n* Histological confirmation of prostate adenocarcinoma requiring radical radiotherapy\n* Gleason score 3+3, 3+4 or 4+3 (Grade groups 1, 2 or 3)\n* MRI stage T2 or less (as staged by AJCC TNM 2018)\n* MRI-visible tumour(s) of PIRADS v2 grade 3 or higher on T2 and diffusion-weighted imaging and\u002For dynamic contrast-enhanced imaging (multiparametric MRI or mpMRI) with concordant pathology\n* Tumour nodule visible on MRI occupying \\\u003C50% of prostate on any axial slice and \\\u003C50% prostate volume\n* PSA \\\u003C20 ng\u002Fml prior to starting ADT (if applicable)\n* Short course (\\\u003C 6 months) concurrent androgen deprivation therapy (antiandrogens or LHRH analogues) allowed though not mandated as per the discretion of the treating physician.\n* WHO Performance status 0-2\n* Ability of the participant understand and the willingness to sign a written informed consent form.\n* Ability\u002Fwillingness to comply with the patient reported outcome questionnaires schedule throughout the study.\n\nExclusion Criteria:\n\n* Contraindications to MRI (e.g. pacemaker, potentially mobile metal implant, claustrophobia)\n* IPSS 19 or higher\n* High grade disease (GG3) occult to MRI-defined lesion\n* Post-void residual \\>100 mls, where known\n* Prostate volume \\>90cc\n* Comorbidities which predispose to significant toxicity (e.g. inflammatory bowel disease) or preclude long term follow up\n* Unilateral or bilateral total hip replacement, or other pelvic metalwork which causes artefact on diffusion-weighted imaging\n* Previous pelvic radiotherapy\n* Patients needing \\>6 months of ADT due to disease parameters as per the discretion of the treating physician\n* Previous invasive malignancy within the last 2 years excluding basal or squamous cell carcinomas of the skin, low risk non-muscle invasive bladder cancer (assuming cystoscopic follow up now negative) or small renal masses on surveillance.","MALE",{"count":74,"type":21},20,[24],"This study is a single centre feasibility trial. The trial will recruit men with intermediate risk localised prostate cancer who will all receive targeted dose (escalated\u002Fde-escalated dose directed by MRI) 5 fraction SBRT to the prostate.\n\nTrial Objectives are:\n\n1. Primary To develop a 5 fraction de-escalated dose SBRT protocol capable of reducing side effects\n2. Secondary\n\n   * To assess levels of acute GU and GI toxicity (CTCAE)\n   * To assess levels of late GU and GI toxicity (CTCAE)\n   * To assess late sexual quality of life (expanded EPIC, IIEF-5)\n   * To assess biochemical relapse-free survival at 2",[78],"Prostate Cancer",[80],"Newly diagnosed intermediate risk localized prostate cancer",{"date":58,"type":34},{"date":83,"type":34},"2023-12-11",{"date":85,"type":21},"2027-12-01",{"name":40,"class":41},{"id":88,"slug":89,"hasResults":12,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":22,"phases":96,"briefSummary":97,"conditions":98,"keywords":100,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":4},"100626373","goal-directed-therapy-to-reduce-kidney-and-cardiovascular-risk-in-diabetic-kidney-disease-gold-standard-100626373","NCT07434791","Goal-Directed Therapy to Reduce Kidney and Cardiovascular Risk in Diabetic Kidney Disease (GOLD-STANDARD)","GOaL Directed-STrategic Approach With New Disease-modifying theraApies to Reduce Kidney and Cardiovascular Risk in Patients With Diabetic Kidney Disease","GOLD-STANDARD","Inclusion Criteria\n\n1. Age ≥ 18 years\n2. T2DM\n3. CKD (eGFR ≥ 25-60 OR UACR ≥ 30 mg\u002Fg)\n4. High Cardiovascular (CV) Risk: Defined as a history of prior myocardial infarction (MI), stroke, or peripheral artery disease (PAD), or the presence of cardiovascular risk factors, (specifically age 40 years or older and at least one of the following: cholesterol above target (LDL≥1.8 mmol\u002FL OR on cholesterol lowering medication), hypertension (≥130\u002F80 mmHg or on BPLMs), or atrial fibrillation.)\n5. Open to start new medications\n\nExclusion Criteria:\n\n1. Type 1 diabetes\n2. HbA1c ≥10% on screening labs\n3. Serum potassium ≥ 5.2 mmol\u002FL on screening labs\n4. Baseline Blood Pressure (BP) \\\u003C 100\u002F60 mmHg at screening\n5. Treated with new or intensified immunosuppression therapy for new (or relapse\u002Fflare of pre-existing) kidney disease within the last 60 days\n6. Kidney Transplant\n7. Use of ≥3 medication classes: Participants already prescribed three or more of the following classes of medications: RASi, SGLT2i, nsMRA or GLP1RA\n8. Intolerance or allergy to any of RASi, SGLT2i, nsMRA or GLP1RA\n9. Known Heart Failure with Reduced Ejection Fraction (HFrEF)\n10. Current pregnancy, lactation or women of childbearing potential, unless using highly effective contraception",{"count":51,"type":21},[24],"GOLD-STANDARD is a pragmatic, open-label pilot randomized controlled trial evaluating the feasibility and safety of early goal-directed Cardio-Kidney-Metabolic (CKM) care compared with usual care in patients with diabetic kidney disease. Participants will be randomized 1:1 and managed by nephrologists.\n\nThe intervention includes structured kidney and cardiovascular risk assessment, early shared decision-making regarding guideline-directed medical therapies, and close monitoring for adverse effects. The usual care group will receive standard clinical management at the discretion of the treating clinician. The study will be conducted in Ontario using existing health care infrastructure.",[99],"Diabetic Kidney Disease (DKD)",[101,102,103,104],"diabetes","diabetic kidney disease","cardiovascular risk","Cardio-Kidney-Metabolic (CKM) care","NOT_YET_RECRUITING","2026-05-01",{"date":108,"type":34},"2026-05-07",{"date":110,"type":21},"2026-06",{"date":112,"type":21},"2029-03",{"name":40,"class":41},{"id":115,"slug":116,"hasResults":12,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":22,"phases":123,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":4},"100606099","this-study-will-use-real-time-pressure-mapping-technology-to-determine-which-positioning-strategies-and-devices-exert-the-least-amount-of-pressure-on-peri-operative-burn-patients-100606099","NCT07171138","This Study Will Use Real-time Pressure Mapping Technology to Determine Which Positioning Strategies and Devices Exert the Least Amount of Pressure on Peri-operative Burn Patients","Pressure Injury Risk Related to Positioning and Positioning Devices in Burn Patients","Inclusion Criteria:\n\n* adult patients (18 years of age or greater)\n* burns of any size\n* pre and post-operative patients\n\nExclusion Criteria:\n\n* pediatric burn patients\n* patients with pre-existing (pre-admission) pressure injuries\n* patients unable to provide informed consent or decline consent\n* patients with large burns that are not expected to survive past 72 hours",{"count":122,"type":21},80,[24],"Burn patients are especially vulnerable to developing hospital-acquired pressure sores. The goal of this study is to determine which positions and positioning devices exert the least amount of pressure on problem areas such as the heels, the tailbone, the elbow and the back of the head.\n\nWith the use of a pressure mapping device, it will allow the investigators to:\n\n1. Identify patients at the highest risk of developing pressure injuries related to positioning\u002Fdevices.\n2. Use the findings to create positioning\u002Fdevice guidelines\n\nBy optimizing positioning strategies, the investigators aim to enhance patient comfort, prevent complications, and ultimately improve the overall quality of care for burn patients.",[126],"Hospital Acquired Pressure Injury",{"date":128,"type":34},"2026-05-05",{"date":130,"type":21},"2026-05",{"date":132,"type":21},"2027-03",{"name":40,"class":41},{"id":135,"slug":136,"hasResults":12,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":141,"sex":17,"minAge":142,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":22,"phases":145,"briefSummary":146,"conditions":147,"keywords":151,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":4},"100583240","neuromodulation-and-fmri-in-neurodegenerative-diseases-study-100583240","NCT06873750","Neuromodulation and fMRI in Neurodegenerative Diseases Study","A Pilot Study in Defining the Potential of Transcranial Alternating Current Neuromodulation for Stabilizing Memory and Improving Functional Connectivity in Neurodegeneration","Inclusion Criteria:\n\n1. Be at least 25 years of age;\n2. Have no contraindications to MRI\n3. Have received 8 or more years of formal education\n4. Be fluent in English\n5. Cohort a. must be followed at Sunnybrook Health Sciences Center\n\nCohort a:\n\n* Have been diagnosed with a suspected neurodegenerative disorder or traumatic brain injury (TBI) with memory deficits impacting functional status\n* In case of TBI, cognitive impairment has persisted at least three months post-injury\n* Received score of 16 or lower on the Mini Mental State Examination (MMSE)\n\nCohort b:\n\n* Have no prior diagnosis of a neurodegenerative disorder or post-traumatic brain injury cognitive deficits\n* Be experiencing healthy aging and be age and sex matched to Cohort a.\n\nExclusion Criteria:\n\n1. Have any contraindications to MRI\n2. Be pregnancy\n3. Have any major comorbid medical conditions (as determined by investigators - e.g., comorbid neurological diseases, uncontrolled hypertension or diabetes, malignancy) or major comorbid psychiatric conditions (as determined by investigators - e.g., schizophrenia or bipolar disorder)",true,"25 Years",{"count":144,"type":21},30,[24],"In addition to neuronal loss, dysfunction in brain network connectivity has been identified as a correlate of cognitive deficits in neurodegenerative and post-traumatic brain injury states. Transcranial alternating current stimulation (tACS) has been suggested as a promising, non-invasive, method of normalizing network connectivity and hence improving cognition, notably memory. This study will examine the efficacy of tACS at improving working memory performance in patients with neurodegeneration and its correlation to changes in network connectivity, based on functional magnetic resonance imaging (fMRI) and electroencephalography (EEG) imaging data.",[148,149,150],"Mild Cognitive Impairment","Traumatic Brain Injury","Neurodegeneration",[152,153,154,155],"Transcranial Alternating Current Stimulation","Neuromodulation","Functional Magnetic Resonance Imaging","Cognitive Assessment","2026-04-27",{"date":106,"type":34},{"date":159,"type":21},"2026-06-01",{"date":161,"type":21},"2028-12-01",{"name":40,"class":41},{"id":164,"slug":165,"hasResults":12,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":22,"phases":172,"briefSummary":173,"conditions":174,"keywords":177,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":189},"100472091","the-canadian-cabg-or-pci-in-patients-with-ischemic-cardiomyopathy-trial-stich3c-100472091","NCT05427370","The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)","The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial","Inclusion Criteria:\n\n1. Age \\>18 years;\n2. LVEF ≤40% quantified by either echocardiography, SPECT ventriculography, or magnetic resonance within 2 months of randomization;\n3. Prognostically important multivessel CAD (triple vessel CAD or double vessel disease including the left anterior descending (LAD) or LM). Significant coronary stenosis is defined as ≥ 70% based on coronary angiography, and\u002For fractional flow reserve (FFR) ≤0.80 or instantaneous wave-free ratio (iFR) ≤0.89. For LM disease, significant coronary stenosis is defined as \\>50% based on coronary angiography, intravascular ultrasound (IVUS) minimal luminal area (MLA) ≤6.0 mm2 (\\\u003C4.5 mm2 Asian descent), or equivalent optical coherence tomography (OCT) measurements;\n4. The institutional Heart Team agrees that guideline-directed medical therapy (GDMT) has been initiated for ≥1 month in prevalent and newly diagnosed cases. In patients hospitalized with newly diagnosed iLVSD (with or without acute coronary syndrome (ACS)) requiring revascularization before discharge, GDMT needs to be initiated, when possible in-hospital before randomization, with the expectation that it will be titrated to maximally tolerated doses after revascularization;\n5. Signed informed consent.\n\nExclusion Criteria:\n\n1. Decompensated HF requiring inotropic\u002Fadrenergic support, invasive or non-invasive ventilation or intra-aortic balloon pump\u002Fventricular assist device therapy less than 48 hours prior to randomization;\n2. Recent (\\\u003C4 weeks) ST-elevation MI;\n3. Concomitant severe valvular disease or other condition such as left ventricular aneurysm requiring surgical repair or replacement;\n4. Planned major concomitant surgical procedures (LAAO and AF ablation surgical procedures permitted);\n5. Prior PCI within the past 12 months (to reduce restenosis events from prior PCIs contributing to the primary outcome);\n6. Prior cardiac surgery;\n7. Prohibitive bleeding risk mandating avoidance of dual antiplatelet therapy;\n8. Circumstances likely to lead to poor treatment adherence;\n9. Severe end-organ dysfunction (such as dialysis, liver failure, respiratory failure, cancer) that reduces life expectancy to less than 5 years;\n10. Current pregnancy;\n11. Patient not amenable to both CABG or PCI according to the Heart Team;\n12. Takotsubo\u002FTakotsubo Cardiomyopathy\u002FBroken Heart Syndrome.",{"count":171,"type":21},754,[24],"The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy (STICH3C) trial is a prospective, unblinded, international multi-center randomized trial of 754 subjects enrolled in approximately 45 centers comparing revascularization by percutaneous coronary intervention (PCI) vs. coronary artery bypass grafting (CABG) in patients with multivessel\u002Fleft main (LM) coronary artery disease (CAD) and reduced left ventricular ejection fraction (LVEF).\n\nThe primary objective is to determine whether CABG compared to PCI is associated with a reduction in all-cause death, stroke, spontaneous myocardial infarction (MI), urgent repeat revascularization (RR), or heart failure (HF) readmission over a median follow-up of 5 years in patients with multivessel\u002FLM CAD and ischemic left ventricular dysfunction (iLVSD).\n\nEligible patients are considered by the local Heart Team appropriate and amenable for non-emergent revascularization by both modes of revascularization.\n\nThe secondary objectives are to describe the early risks of both procedures, and a comprehensive set of patient-reported outcomes longitudinally.",[175,176],"Coronary Artery Disease","Heart Failure Systolic",[178,179,180,181],"Left ventricular dysfunction","CABG","PCI","MACCE",{"date":183,"type":34},"2026-04-28",{"date":185,"type":34},"2023-06-22",{"date":187,"type":21},"2029-12",{"name":40,"class":41},43,{"id":191,"slug":192,"hasResults":12,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":22,"phases":200,"briefSummary":201,"conditions":202,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":204,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":42},"100441049","assessment-of-quality-of-life-and-outcomes-in-patients-with-primary-renal-cell-carcinoma-treated-with-sbrt-100441049","NCT05023265","Assessment of Quality of Life and Outcomes in Patients With Primary Renal Cell Carcinoma Treated With SBRT","Assessment of Quality of Life and Outcomes in Patients Treated With Stereotactic Body Radiotherapy (SBRT) for Inoperable Renal Cell Carcinoma (RCC): A Multicenter Phase II Study","AQuOS-II","Inclusion Criteria:\n\n* Patients ≥18 years old\n* Newly diagnosed RCC by biopsy (preferred) or radiologic evidence of growth on surveillance over two consecutive assessments (6-12 months)\n* Primary lesion \\>3 cm, or recurrent lesion following local ablative therapy\n* Medically inoperable or patient who refuses surgery following assessment by experienced urologist, and discussed in a multidisciplinary setting\n* ECOG 0-2\n* Written informed consent\n* Participants must be able to understand the English-language or with the aid of a translator\n\nExclusion Criteria:\n\n* Primary Lesion \\>20cm\n* Evidence of distant metastatic disease\n* Previous abdominal RT in vicinity of kidney preventing definitive SBRT\n* History of major radiosensitivity syndrome\n* Second invasive malignancy within the past 3 years (excluding non-melanomatous skin cancer)\n* Currently pregnant or lactating",{"count":199,"type":21},70,[24],"This is a multicenter, single arm phase II study of stereotactic body radiation therapy (SBRT) for patients with medically inoperable primary renal cell carcinoma (RCC).",[203],"Renal Cell Carcinoma",{"date":183,"type":34},{"date":206,"type":34},"2022-02-08",{"date":208,"type":21},"2026-10-01",{"name":40,"class":41},{"id":211,"slug":212,"hasResults":12,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":12,"sex":17,"minAge":142,"maxAge":4,"enrollmentInfo":217,"targetDuration":4,"studyType":22,"phases":218,"briefSummary":219,"conditions":220,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":229},"100582471","using-cannabis-to-treat-restless-legs-syndrome-100582471","NCT06863740","Using Cannabis to Treat Restless Legs Syndrome","Using Cannabis to Treat Restless Legs Syndrome: A Randomized Placebo Controlled Pilot Safety and Feasibility Trial","Inclusion Criteria:\n\n* ≥25 years of age\n* diagnosis of RLS based on the International RLS Study Group criteria\n* refractory RLS symptoms despite use of dopaminergic and\u002For alpha-2-delta ligand therapy\n* onset of RLS at least 6 months before screening\n\nExclusion Criteria:\n\n* sleep disordered breathing, or sleep disordered breathing that is not adequately controlled on therapy (apnea-hypopnea index of \\>15)\n* cannabis use within 4 weeks of study enrollment\n* known allergy to cannabis, cannabinoids or palm\u002Fcoconut oil\n* Currently pregnant or breast-feeding (a negative urine pregnancy test must be obtained for women of childbearing potential during pretreatment evaluation)\n* Active substance abuse\n* Ischemic heart disease with unstable angina or recent acute coronary syndrome in the last 3 months, uncontrolled arrhythmias, poorly controlled hypertension\n* Serious liver disease\n* History of schizophrenia or any other psychotic disorder",{"count":144,"type":21},[24],"Restless Legs Syndrome (RLS) is a disorder that causes painful and uncomfortable sensations in the legs, and its symptoms have a significant impact on sleep and quality of life. Cannabis has been used by some RLS patients as a treatment due to its painkilling and drowsiness effects, however there has never been a clinical research trial investigating cannabis in patients with RLS. A controlled trial is needed to establish how safe and feasible cannabis is as a treatment for RLS. The investigators plan to randomize 30 participants with moderate-to-severe RLS to receive either cannabis or placebo for 8 weeks. The investigators will measure patients sleep quality and quality of life at baseline and 8-week follow-up. The investigators will also monitor patients for any adverse reactions to the study drug.",[221],"Restless Leg Syndrome (RLS)","2026-04-22",{"date":183,"type":34},{"date":225,"type":34},"2025-07-25",{"date":227,"type":21},"2027-05",{"name":40,"class":41},2,{"id":231,"slug":232,"hasResults":12,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":236,"eligibilityCriteria":237,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":238,"targetDuration":4,"studyType":22,"phases":240,"briefSummary":241,"conditions":242,"keywords":245,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":256},"100502942","clinical-evaluation-of-antiseptic-skin-preparation-in-revision-total-joint-arthroplasty-of-the-hip-and-knee-100502942","NCT05828810","CLinical Evaluation of ANtiseptic Skin Preparation in Revision Total Joint Arthroplasty of the Hip and Knee","CLinical Evaluation of ANtiseptic Skin Preparation in Revision Total Joint Arthroplasty of the Hip and Knee - A Vanguard Randomized Controlled Registry Trial (CLEAN Joint Trial)","CLEANJoint","Inclusion Criteria:\n\n1. Aged 18 years or older\n2. Scheduled to undergo aseptic revision total hip arthroplasty or total knee arthroplasty with exchange of at least one prosthetic component\n\nExclusion Criteria:\n\n1. Revision for prosthetic joint infection or wound complication\n2. Known history of previous prosthetic joint infection in the operative joint\n3. Any degree of clinical concern for prosthetic joint infection\n4. History of allergy to iodine, chlorhexidine, or alcohol",{"count":239,"type":21},400,[24],"The goal of this clinical trial is to compare two types of skin preparation solutions (chlorhexidine gluconate-alcohol solution and povidone-iodine solution) that help eliminate harmful bacteria on the skin at the time of surgery for patients having revision arthroplasty surgery of the hip or knee.\n\nThe main outcome of interest for the definitive study is the need for re-operation for a wound complication or an infection of the prosthetic joint within one year after surgery.\n\nFor the pilot trial, our main interest is to determine feasibility of a definitive trial. Feasibility outcomes will include: ability to recruit patients, ability to randomize patients, ability to collect complete data, estimate the event rate of our primary outcome, ability to carry out data linkages and determine the accuracy of collected data.\n\nParticipants will be contacted at two time points after surgery to complete a 5-minute survey: after 30 days, and after 1 year.",[243,244],"Revision Total Hip Arthroplasty (RTHA)","Revision Total Knee Arthroplasty",[246,247,248],"prosthetic joint infection","registry-based RCT","PJI",{"date":250,"type":34},"2026-04-24",{"date":252,"type":34},"2023-07-25",{"date":254,"type":21},"2026-11",{"name":40,"class":41},3,{"id":258,"slug":259,"hasResults":12,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":22,"phases":266,"briefSummary":267,"conditions":268,"keywords":270,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":277,"locationsCount":42},"100491358","oropharyngeal-exercises-to-treat-obstructive-sleep-apnea-100491358","NCT05678088","Oropharyngeal Exercises to Treat Obstructive Sleep Apnea","Strengthening Oropharyngeal Muscles as a Novel Approach to Treat Obstructive Sleep Apnea: A Randomized Feasibility Study","Inclusion Criteria:\n\n* Patients with OSA (defined as an apnea-hypopnea index ≥10\u002Fhr) in whom \\>50% of the respiratory events are obstructive in nature\n* Patients who are unwilling to use CPAP or have been unable to tolerate CPAP after at least a 2-week trial\n* Patients who are also not using an equipment-based treatment modality (e.g. PAP therapy, a dental appliance, or hypoglossal nerve stimulation) or surgery to manage their OSA.\n\nExclusion Criteria:\n\n* Planned airway surgery, use of CPAP, a dental appliance, or other equipment-based treatment modality to manage OSA during the course of the study\n* Central respiratory events account for ≥50% of the overall apnea-hypopnea index\n* Reduced cognition (MoCA\\\u003C18)\n* Any significant neurological condition that could impact oropharyngeal activity\n* Use of medications that may impact tone of the upper airway (e.g. hypnotics, opiates) ≥3 nights per week during the 4 weeks prior to randomization\n* Use of a medical device that would interfere with the use of the home sleep apnea test\n* Plans to move to another city during the study that would impact compliance.",{"count":265,"type":21},45,[24],"The goal of this study is to determine whether a randomized controlled trial using oropharyngeal exercises to treat sleep apnea is feasible. Continuous positive airway pressure (CPAP) is the standard therapy for Obstructive sleep apnea (OSA), but it is poorly tolerated by many patients. Oropharyngeal exercises (OPEs) which are commonly used by speech-language pathologists to improve oro-motor strength, may serve as a promising alternative approach. The main questions this study aims to answer are:\n\n* Is it feasible to use an oropharyngeal exercise protocol in patients with sleep apnea?\n* Will oropharyngeal exercises improve sleep apnea severity, daytime sleepiness, sleep quality, mood, workplace performance, and quality of life\n\nParticipants will be randomized into a supervised OPE intervention arm vs. unsupervised OPE intervention arm vs. sham treatment for a 10-week\u002F5-day per week\u002Ftwo 20-minute session exercise protocol. The exercises will be administered via an app and the investigators will assess feasibility, as well as several sleep-related and oro-motor physiological outcomes before treatment, immediately post-treatment, and 4 weeks post-treatment. The investigators will use the results of this feasibility trial to inform the sample size needed for a larger clinical trial that will determine the efficacy of using oropharyngeal exercises to treat OSA.",[269],"Obstructive Sleep Apnea",[269,271],"Oropharyngeal Exercises","2026-04-21",{"date":250,"type":34},{"date":275,"type":34},"2023-03-28",{"date":132,"type":21},{"name":40,"class":41},{"id":279,"slug":280,"hasResults":12,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":284,"eligibilityCriteria":285,"healthyVolunteers":12,"sex":286,"minAge":18,"maxAge":4,"enrollmentInfo":287,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":289,"conditions":290,"keywords":292,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":42},"100635530","baseline-knowledge-of-stress-urinary-incontinence-among-urogynecology-patients-100635530","NCT07553884","Baseline Knowledge of Stress Urinary Incontinence Among Urogynecology Patients","Knowledge, Awareness, and Understanding of Stress Urinary Incontinence in Patients Attending a Urogynecology Clinic","SUI","Inclusion Criteria:\n\n* Participants are patients referred to Sunnybrook Health Sciences Centre Urogynecology Clinics with the condition of SUI.\n* ≥ 18 years old\n* Female\n* Able to provide informed consent and communicate in English\n\nExclusion Criteria:\n\n* Under the age of 18 years\n* Urge-predominant mixed urinary incontinence or pure urinary urge incontinence\n* Inability to respond to research questionnaires in English\n* Unable to provide informed consent","FEMALE",{"count":288,"type":21},90,"The goal of this prospective study is to assess whether a standardized educational flyer (pamphlet) improves knowledge about stress urinary incontinence (SUI) in adult females attending a urogynecology clinic. It will also explore how participant characteristics relate to treatment preferences.\n\nThe main questions it aims to answer are:\n\nDoes reading a standardized SUI patient information flyer improve participants' knowledge of SUI? How do patient characteristics influence treatment preferences for SUI?\n\nParticipants will:\n\nComplete a self-administered questionnaire assessing knowledge of SUI, including its definition, pathophysiology, risk factors, natural history, and treatment options (this questionnaire is not part of standard care).\n\nReview a standardized SUI educational flyer during their clinic visit. Complete the same questionnaire again after reading the pamphlet to assess any change in knowledge.\n\nQuestionnaire scores before and after reading the flyer will be compared. Secondary outcomes include participant characteristics and reported treatment preferences.",[291],"Stress Urinary Incontinence (SUI)",[293],"prospective cohort","2026-04-20",{"date":183,"type":34},{"date":297,"type":21},"2026-04-30",{"date":299,"type":21},"2026-07-31",{"name":40,"class":41},{"id":302,"slug":303,"hasResults":12,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":307,"eligibilityCriteria":308,"healthyVolunteers":12,"sex":17,"minAge":309,"maxAge":4,"enrollmentInfo":310,"targetDuration":4,"studyType":22,"phases":312,"briefSummary":314,"conditions":315,"keywords":323,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":334,"locationsCount":42},"100614447","phase-2-fisetin-in-mild-alzheimers-disease-100614447","NCT07279714","Fisetin in Mild Alzheimer's Disease","Fisetin Intervention Study in Mild Alzheimer's Disease","FIS-AD","Inclusion Criteria:\n\n* Mild cognitive impairment due to Alzheimer's disease OR mild Alzheimer Dementia\n* Moca score of 11 or higher\n* Stable psychotropics and cognitive enhancing medications\n\nExclusion Criteria:\n\n* Known hypersensitivity or allergy to fisetin\n* Presence of any medical condition, or abnormal routine blood test, that the investigator believes would put the subject at risk or would preclude the patient from completing all aspects of the trial\n* Unstable medical disorders\n* Ongoing treatment for active infection with antibiotics\u002Fantifungals\n* Ongoing treatment for cancer\n* Active alcohol or substance use disorder\n* Recent active bleeding\n* Patients taking oral anticoagulants, anti-cancer, anti-seizure medications, or other medications that could have a significant interaction with fisetin\n* Use within the last month of other senolytic supplements, antioxidant supplements, natural health products\n* Other neurologic or neurodegenerative conditions impacting cognition\n* Active Major Depressive Episode, active suicidal thoughts or psychosis\n* Any thing that would preclude the ability to undergo an MRI scan","60 Years",{"count":311,"type":21},5,[313],"PHASE2","This pilot study will evaluate the safety and tolerability of the natural health product, fisetin, in older adults with mild cognitive impairment or mild Alzheimer's disease dementia.",[316,317,318,319,320,321,322],"Alzheimer s Disease","Alzheimer Dementia","Alzheimer Dementia (AD)","Alzheimer Disease","Mild Cognitive Disorder","Neurocognitive Disorders, Mild","Neurocognitive Disorder",[324,325,326,327],"fisetin","alzheimer's disease","safety","tolerability","2026-04-10",{"date":330,"type":34},"2026-04-13",{"date":332,"type":34},"2026-01-27",{"date":254,"type":21},{"name":40,"class":41},{"id":336,"slug":337,"hasResults":12,"nctId":338,"briefTitle":339,"officialTitle":340,"acronym":341,"eligibilityCriteria":342,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":343,"targetDuration":4,"studyType":22,"phases":345,"briefSummary":347,"conditions":348,"keywords":350,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":360,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":311},"100611834","phase-4-oral-versus-intramuscular-steroid-use-to-control-rheumatoid-arthritis-flares-100611834","NCT07245732","Oral Versus Intramuscular Steroid Use to Control Rheumatoid Arthritis Flares","STeroid Options for RA Management (STORM-RA): Oral Versus Intramuscular Steroid Use to Control Rheumatoid Arthritis Flares: A Pragmatic Randomized Clinical Trial","STORM-RA","Inclusion Criteria:\n\n* Rheumatologist verified RA diagnosis.\n* Patients are allowed to be on non-steroidal anti-inflammatory drugs (NSAIDs) prior to randomization, but the dosages must be stable for ≥2 weeks prior to randomization.\n* Patients must be on stable doses of conventional synthetic disease-modifying antirheumatic drugs (csDMARD)\u002Ftargeted synthetic disease-modifying antirheumatic drugs (tsDMARD)\u002Fbiologics (bDMARDs) for ≥8 weeks prior to randomization.\n\nExclusion Criteria:\n\n* Allergies, intolerances or contraindications to systemic GCs or IM injections\n* Patients with active malignancy, are pregnant or breastfeeding.\n* Patients who have received systemic or intra-articular GC within 4-weeks of randomization.",{"count":344,"type":21},220,[346],"PHASE4","People living with rheumatoid arthritis (RA) often experience flares-periods where their symptoms suddenly get worse. These flares can cause significant pain, make it harder to move and do daily activities, and lower overall quality of life. Doctors often treat flares with medications called glucocorticoids (GCs), which reduce inflammation. These medications can be taken by mouth (oral\u002FPO) or given as a single injection into the muscle (intramuscular\u002FIM). However, it's not clear which option works better from the patient's point of view-especially when it comes to relief of symptoms, improvements in function, and satisfaction with treatment. Most research so far has focused on how well the drugs control the disease, rather than how they impact the patient's overall experience.\n\nResearch Questions:\n\n1. Does a single GC injection work just as well as taking pills over a few weeks in improving symptoms reported by patients?\n2. How do the two treatments compare in terms of symptom relief, ability to function, and patient satisfaction?\n3. What do patients think and feel about using GCs to treat RA flares?\n\nWhat the Investigators Think:\n\nThe investigators believe that a one-time GC injection is just as good as taking pills for a few weeks when it comes to managing RA flares. In fact, the injection might even be safer and preferred by patients.\n\nWhat the Investigators are Doing:\n\nThe investigators will study 220 adults with RA who are currently having a flare (with at least 3 swollen and tender joints). These patients will be recruited from rheumatology clinics at the University of Toronto and must not have used GCs in the past month. They will be randomly assigned to receive either:\n\nA single injection (Methylprednisolone 120 mg), or Oral pills (Prednisone starting at 15 mg daily and tapering down over 3 weeks).\n\nThe main thing the investigators will look at is how much better patients feel after 6 weeks, based on a questionnaire designed to measure RA flares. The investigators will also look at how well they function, how satisfied they are with the treatment, and whether they had any side effects.\n\nIn addition, 20 patients (10 from each group) will be interviewed to understand their experiences and opinions about flare treatment in more detail.\n\nWhy This Is Possible:\n\nThe investigators have already surveyed University of Toronto rheumatologists who support the idea and provided input on study design. The investigators have also partnered with experts in research methods, national arthritis organizations, and patient groups to make sure the study is relevant and meaningful. Ethics approval has been obtained.\n\nWhy It Matters:\n\nRA flares can have a major impact on people's lives. While current treatments help control inflammation, the investigators need to better understand how these treatments affect people from their own perspective. This study will shift the focus to what matters most to patients, helping doctors and patients choose the best treatment based not only on medical results but also on the patient's experience. This could lead to more effective and personalized care for people living with RA.",[349],"Rheumatoid Arthritis (RA)",[351,352,353,354,355,356,357,358,359],"Pragmatic trial","Qualitative study","Study within a trial (SWAT)","Steroids","Rheumatoid arthritis","Quality of life","Disease flare","Patient reported outcomes","Adverse effects",{"date":330,"type":34},{"date":362,"type":21},"2026-04",{"date":364,"type":21},"2029-07",{"name":40,"class":41},{"id":367,"slug":368,"hasResults":12,"nctId":369,"briefTitle":370,"officialTitle":371,"acronym":372,"eligibilityCriteria":373,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":374,"targetDuration":4,"studyType":22,"phases":376,"briefSummary":377,"conditions":378,"keywords":380,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":384,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":390,"locationsCount":42},"100560583","the-heroes-trial-hyperbaric-oxygen-therapy-for-endometriosis-related-pain-100560583","NCT06579040","The HEROES Trial: Hyperbaric Oxygen Therapy for Endometriosis-Related Pain","The HEROES Trial: Hyperbaric Oxygen Therapy for Endometriosis-Related Pain: A Prospective Randomized Study","HEROES","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Patients having refractory pelvic pain (NRS≥4) secondary to endometriosis for \\>6 months\n* May or may not be on traditional multi-modal treatment (pharmacological and\u002For non-pharmacological)\n* On waitlist for surgical treatment\n\nExclusion Criteria:\n\n* Patients with chronic pain resulting from disease processes unrelated to the pathophysiology of endometriosis-related symptoms (e.g. irritable bowel syndrome, migraine headache, fibromyalgia, chronic low back pain, and musculoskeletal injuries)\n* Contraindications\u002Fmedically unfit to receive hyperbaric treatments at an outpatient facility (e.g. pneumothorax, in-patients, requiring infusions to maintain hemodynamics, active and unstable coronary disease)\n* Unlikely to comply with follow-up assessments (e.g. no fixed address, plans to move out of town)",{"count":375,"type":21},64,[24],"Endometriosis, is a condition where tissue from the uterus, called endometrium, grows outside of the uterus. This effects up to 10% of women, and can lead to long-lasting, moderate to severe pelvic pain, infertility and other symptoms. This can affect a woman's quality of life (including increased risk of depression and anxiety) and is associated with increased healthcare costs.\n\nCurrent treatments are often limited by serious side effects, and many women resort to surgery. Surgery is also associated with complications and there are long wait times for procedures, sometimes over 3 years. This means that many women continue to suffer from symptoms while they wait for surgery. Therefore, new effective treatments for endometriosis pain are needed.\n\nNew research suggests that inflammation and stress caused by lack of oxygen in the affected areas may cause endometriosis. Hyperbaric Oxygen Therapy (HBOT), where patients are placed in a small chamber with higher than normal levels of oxygen, suppresses inflammation and promotes tissue healing. Because inflammation is central to this condition, HBOT has emerged as a potential treatment.\n\nIn this study, the investigators will test if HBOT, in addition to the standard treatments, is more effective at treating endometriosis pain than the standard treatments alone.",[379],"Endometriosis-related Pain",[381,379,382,383],"Endometriosis","Hyperbaric Oxygen Therapy","HBOT",{"date":385,"type":34},"2026-04-15",{"date":387,"type":34},"2025-04-08",{"date":389,"type":21},"2027-12",{"name":40,"class":41},{"id":392,"slug":393,"hasResults":12,"nctId":394,"briefTitle":395,"officialTitle":396,"acronym":397,"eligibilityCriteria":398,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":399,"targetDuration":4,"studyType":22,"phases":401,"briefSummary":402,"conditions":403,"keywords":408,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":413,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":418,"locationsCount":42},"100482374","rtms-for-apathy-clinical-trial-100482374","NCT05561205","rTMS for Apathy Clinical Trial","Repetitive Transcranial Magnetic Stimulation for Apathy Clinical Trial (REACT)","REACT","Inclusion Criteria:\n\n* mild or major neurocognitive disorder OR mild behavioural impairment\n* Apathy for at least 4 weeks\n* Stable dose of medication (\\>4 weeks) that may affect cognition or behaviour\n* Care partner who spends at least 10 hours a week with the subject\n\nExclusion Criteria:\n\n* Current major depressive episode\n* Agitation, delusions, hallucination\n* Medical contraindications to rTMS\n* Currently taking an amphetamine product\n* Central nervous system abnormalities, Tourette's syndrome, or motor tics\n* Current participation in another clinical trial",{"count":400,"type":21},10,[24],"Apathy is a common, early, and disabling symptom in dementias and mild behavioural impairment such as Alzheimer's disease (AD) and is characterized by lack of interest and enthusiasm. Both repetitive transcranial magnetic stimulation (rTMS), a form of non-invasive brain stimulation, and methylphenidate, a medication, have been shown to improve apathy. This pilot study will investigate rTMS as a treatment for apathy in neurocognitive disorders and mild behavioural impairment in individuals receiving methylphenidate and individuals not receiving medication for apathy.",[319,404,405,406,148,407],"Apathy in Dementia","Dementia","Mild Behavioural Impairment","Neurocognitive Disorders",[409,410,411,412],"Apathy","Alzheimer's disease","Neurocognitive disorder","Mild behavioural impairment",{"date":330,"type":34},{"date":415,"type":34},"2023-02-09",{"date":417,"type":21},"2026-12-01",{"name":40,"class":41},{"id":420,"slug":421,"hasResults":12,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":425,"eligibilityCriteria":426,"healthyVolunteers":12,"sex":17,"minAge":427,"maxAge":4,"enrollmentInfo":428,"targetDuration":4,"studyType":22,"phases":429,"briefSummary":430,"conditions":431,"keywords":433,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":440,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":444,"locationsCount":42},"100445363","exercise-as-a-primer-for-brain-stimulation-in-vascular-cognitive-impairment-no-dementia-vcind-100445363","NCT05079464","Exercise as a Primer for Brain Stimulation in Vascular Cognitive Impairment No Dementia (VCIND)","Exercise as a Primer for Excitatory Stimulation Study in Vascular Cognitive Impairment No Dementia (EXPRESS-V)","EXPRESS-V","Inclusion Criteria:\n\n* ≥50 years of age; females must be post-menopausal\n* Presence of cerebrovascular and\u002For cardiovascular risk factors or coronary artery disease\n* Montreal Cognitive Assessment (MoCA) \\\u003C27\n* Sufficiently proficient in English\n* Must be able to exercise at a moderate intensity level\n* Presence of modest deficits (1 standard deviation below population norm) in one of the following domains: executive function, verbal memory, working memory, or visuospatial memory\n\nExclusion Criteria:\n\n* History of stroke\n* Change in psychotropics within the last 4 weeks\n* Current benzodiazepine use due\n* Metal implants that would preclude safe use of tDCS or neuroimaging\n* Significant neurological or psychiatric conditions (current major depressive disorder, bipolar disorder, schizophrenia)\n* MoCA \\\u003C18 and\u002For clinical diagnosis of dementia\n* Any medical contraindications to exercise","50 Years",{"count":375,"type":21},[24],"People with vascular conditions are at risk of having memory problems, and these memory problems increase the risk for further cognitive decline. Brain stimulation has been used to improve mood and memory. Transcranial direct current stimulation (tDCS) is believed to work best on brain cells that are active or \"primed\" before stimulation. The purpose of this study is to compare the effects of exercise and tDCS on memory performance in patients who have completed cardiac rehabilitation and are at risk of cognitive decline.",[432,148],"Vascular Cognitive Impairment",[434,435,436,437,438,439],"transcranial direct current stimulation","tDCS","exercise","cognition","vascular cognitive impairment no dementia","vascular mild cognitive impairment",{"date":330,"type":34},{"date":442,"type":34},"2021-11-22",{"date":38,"type":21},{"name":40,"class":41},{"id":446,"slug":447,"hasResults":12,"nctId":448,"briefTitle":449,"officialTitle":449,"acronym":4,"eligibilityCriteria":450,"healthyVolunteers":12,"sex":286,"minAge":18,"maxAge":4,"enrollmentInfo":451,"targetDuration":4,"studyType":22,"phases":453,"briefSummary":454,"conditions":455,"keywords":459,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":466,"completionDateStruct":467,"leadSponsor":468,"locationsCount":42},"100632314","phase-2-a-dose-optimization-study-of-enzalutamide-in-elderly-patients-with-advanced-prostate-cancer-100632314","NCT07512076","A Dose Optimization Study of Enzalutamide in Elderly Patients With Advanced Prostate Cancer","Inclusion Criteria:\n\nMain Cohort:\n\n1. Male aged 75 years or older.\n2. Signed Informed Consent Form\n3. Advanced prostate cancer with a Health Canada approved indication for enzalutamide amongst the following:\n\n   1. High-risk biochemical recurrent hormone sensitive prostate cancer (high risk definition: PSA doubling time of ≤9 months and a PSA level of ≥2 ng per milliliter above nadir after radiation therapy or ≥1 ng per milliliter after radical prostatectomy with or without postoperative radiation therapy).\n   2. Metastatic castration-sensitive prostate cancer.\n   3. Non-metastatic castration-resistant prostate cancer (M0CRPC) with a PSA doubling time of ≤9 months\n4. Participants must receive concomitant androgen deprivation therapy with either a Luteinizing hormone-releasing hormone (LHRH) antagonist or agonist, or have had bilateral orchiectomy.\n5. Participant is capable, in the opinion of the investigator, of completing all study assessments and procedures, including blood draws for PK sampling according to the required schedule as per the study protocol as well as PROs.\n\n   1. Note, for patients who speak a language other than English, PROs may be completed with the help of an interpreter, or translated PROs may be substituted, if available in the patient's primary language.\n\nControl Cohort:\n\n1. Age \\\u003C 70 years\n2. Receiving enzalutamide for advanced prostate, for any indication as per Product Monograph\n3. Receiving the same dose of enzalutamide taken daily and fully compliant for ≥ 29 days\n4. Signed Informed Consent Form\n\nExclusion Criteria:\n\nMain Cohort:\n\n1. Metastatic castration-resistant prostate cancer\n2. Pain related to bone metastasis requiring the use of opioid analgesics\n3. Impending spinal cord compression related to metastasis to vertebral column\n4. Painful femoral neck or any other metastasis judged to be at risk of short-term pathological fracture in the investigator's opinion\n5. Co-administration of medications which are moderate to strong CYP2C8 inducers or inhibitors\n6. Co-administration of medications which are moderate to strong CYP3A4 inducers or inhibitors\n7. History of seizure disorder\n8. History of moderate-severe dementia\n9. Performance status \\> ECOG 2\n10. Uncontrolled hypertension (defined as sustained systolic blood pressure above 160 and\u002For diastolic above 100 despite the adequate use of antihypertensive medication)\n11. Participants with a known history of dementia, seizure disorder, intracranial lesions, moderate to severe hepatic impairment, stage ≥ 3 chronic renal failure or stroke will also be excluded\n\nControl Cohort:\n\n1. Unable to provide written informed consent\n2. Receiving a medication which is a moderate-strong CYP2C8 or CYP3A4 inducer or inhibitor",{"count":452,"type":21},26,[313],"This is a phase II, single-centre, pragmatic, non-randomized, dose escalation study to evaluate optimal dose levels of enzalutamide in elderly patients using pharmacokinetic blood sampling concentrations.",[456,457,458],"Prostate Cancer Patients","Elderly Patients","Pharmacokinetic Study",[460,461,462],"prostate cancer","enzalutamide","elderly patients","2026-03-31",{"date":465,"type":34},"2026-04-06",{"date":362,"type":21},{"date":389,"type":21},{"name":40,"class":41},{"id":470,"slug":471,"hasResults":12,"nctId":472,"briefTitle":473,"officialTitle":474,"acronym":475,"eligibilityCriteria":476,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":477,"enrollmentInfo":478,"targetDuration":4,"studyType":22,"phases":480,"briefSummary":481,"conditions":482,"keywords":485,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":493,"startDateStruct":495,"completionDateStruct":497,"leadSponsor":499,"locationsCount":42},"100521692","phase-2-a-randomized-neuroimaging-trial-of-psilocybin-in-depression-100521692","NCT06072898","A Randomized Neuroimaging Trial of Psilocybin in Depression","Engaging Mood Brain Circuits With Psilocybin: a Randomized Neuroimaging Trial in Depression","EMBRACE","Inclusion Criteria:\n\n* Able and voluntarily willing to provide written informed consent at the screening visit\n* Over 18 and under 65 years old\n* Able to complete all protocol required assessment tools without any assistance or alteration to the copyrighted assessments, and to comply with all study visits\n* Must have a responsible individual\u002Fcaregiver who is able to monitor the participant at home for 24 hours after each treatment visit in the study\n* Must have a psychiatrist and\u002For general practitioner who is able to provide psychiatric follow-up care\n* Have a Mini-International Neuropsychiatric Interview (MINI) confirmed diagnosis of MDD, recurrent or single episode without psychotic features where the duration of the current episode is at least 3 months\n* Depression of at least moderate severity as defined by a Hamilton Depression Rating Scale (HAMD-17) score \\>17\n\nExclusion Criteria:\n\n* Current or past history of bipolar I\u002FII disorder, schizophrenia, schizoaffective disorder, psychotic disorder, or delusional disorder as assessed by a structured clinical interview (MINI)\n* A clinical diagnosis of antisocial personality disorder and\u002For paranoid personality disorder (defined as meeting DSM-5 criteria) based on clinical interview and the MINI 7.0. Positive diagnoses on the MINI will be subject to confirmation at a clinical interview by a psychiatrist.\n* An active clinical diagnosis of borderline personality disorder as confirmed by the MINI 7.0.\n* Depression secondary to other medical conditions or bipolar I and II disorder\n* Family history of a first degree relative with a diagnosis of schizophrenia or a primary psychotic disorder and\u002For bipolar disorder\n* Any symptoms consistent with psychosis\n* Any symptoms consistent with hypomania and\u002For mania as assessed by a psychiatrist\n* Personal history of ≥ 1 suicide attempt in the past year requiring hospitalization, defined using the Columbia Suicide Severity Rating Scale (CSSRS) (Q6 (past year) = \"y\") and clinical interview with a psychiatrist\n* Other personal circumstances or behavior judged to be incompatible with establishment of rapport or safe exposure to psilocybin\n* Women who are pregnant (self-report or via urine test), nursing, or planning a pregnancy\n* Lifetime history of substance use disorder with a hallucinogen\n* Lifetime history of substance-induced psychosis\n* Positive urine drug screen for illicit drugs or drugs of abuse at screening, a week prior to treatment, and during the trial (any positive urine drug test will be reviewed with participants to determine the pattern of use and eligibility will be determined at the investigator's discretion)\n* Abnormal and clinically significant results on a physical examination performed within one month of study participation by a general practitioner, vital signs, ECG, or laboratory test at screening\n* QTc prolongation on ECG\n* Uncontrolled or insulin-dependent diabetes\n* History of seizure disorder except for seizures from electroconvulsive therapy and\u002For febrile seizures in childhood\n* Diagnosis of any mild or major neurocognitive disorder meeting DSM-5 criteria and based on clinical interview\u002Fcognitive screening by a psychiatrist\n* History of stroke, recent myocardial infarction (\\\u003C 1 year from signing of ICF), uncontrolled hypertension (blood pressure \\> 140\u002F90 mmHg) or clinically significant arrhythmia within 1 year of signing the ICF\n* Any other clinically significant cardiovascular, pulmonary, gastrointestinal, hepatic, renal or any other major concurrent illness that, in the opinion of the investigator, may interfere with the interpretation of the study results or constitute a health risk for the participant if he\u002Fshe takes part in the study\n* Exposure to psilocybin or any other psychedelic in the past 12 months prior to screening and\u002For during the current MDE and use of psychedelics, such as ayahuasca\u002FLSD, during the current depressive episode\n* History of substance use and\u002For alcohol use disorder, of moderate severity or greater, in the past 12 months\n* Current enrolment in an interventional study for depression or participation in such within 30 days of screening\n* Serial blood counts to achieve a value to meet eligibility - abnormalities in screening\u002Fbaseline blood work (complete blood counts, electrolyte panel, etc.) will be reviewed by MD, then repeated serially until abnormalities resolve.","64 Years",{"count":479,"type":21},50,[313],"The goal of this neuroimaging clinical trial is to test whether psilocybin produces significant immediate changes in functional brain activity in networks associated with mood regulation and depression compared to placebo in patients with depression. The trial aims to determine if psilocybin:\n\n1. Changes connectivity within brain networks associated with mood and depression\n2. Changes blood flow in brain regions associated with mood and depression\n\nParticipants will be attend two treatment sessions where they receive an oral medication and supportive psychotherapy. At each session, participants will undergo an MRI scan after drug administration but prior to psychotherapy. Participants will be randomly to assigned to one of two groups that will receive, 1) microcrystalline cellulose (25mg) at the first visit and psilocybin (25mg) at the second visit, or 2) psilocybin (25mg) at both visits, respectively. Differences between groups will be compared to understand what effects on brain activity are specific to psilocybin.",[483,484],"Depressive Disorder","Major Depressive Disorder",[486,487,488,489,490,491],"Psilocybin","Neuroimaging","MRI","Depression","Psychotherapy","Psychedelic","2026-03-24",{"date":494,"type":34},"2026-03-30",{"date":496,"type":34},"2025-05-28",{"date":498,"type":21},"2029-05",{"name":40,"class":41},{"id":501,"slug":502,"hasResults":12,"nctId":503,"briefTitle":504,"officialTitle":505,"acronym":506,"eligibilityCriteria":507,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":508,"targetDuration":4,"studyType":22,"phases":510,"briefSummary":511,"conditions":512,"keywords":514,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":519,"lastUpdatePostDateStruct":520,"startDateStruct":522,"completionDateStruct":524,"leadSponsor":526,"locationsCount":42},"100629835","optimizing-ventilation-to-improve-survival-from-out-of-hospital-cardiac-arrest-the-optivo-randomized-controlled-trial-100629835","NCT07479836","Optimizing Ventilation to Improve Survival From Out-of-hospital Cardiac Arrest: the OPTIVO Randomized Controlled Trial","OPTImizing Ventilation to Improve Survival From Out-of-Hospital Cardiac Arrest: The OPTIVO Randomized Controlled Trial","OPTIVO","Inclusion Criteria:\n\n* Adult (\\>=18 years of age)\n* presumed cardiac etiology\n* treated by paramedics\n* Ventilation monitor utilized\n\nExclusion Criteria:\n\n* Do Not Resuscitate (DNR) order\n* No use of ventilation monitor\n* Traumatic cardiac arrest\n* Pregnant patients\n* Prisoners\n* Respiratory cause of cardiac arrest (e.g. drowning, hanging, suffocation, opioid-related)",{"count":509,"type":21},1656,[24],"When the heart stops pumping during cardiac arrest, cardiopulmonary resuscitation (CPR) is used to continue pushing blood and providing oxygen to vital organs. CPR involves a combination of chest compressions (to push the blood) and ventilations (to provide oxygen and gas exchange). There is a lot of research that has helped to optimize the provision of chest compressions, however there is considerably less research available to guide ventilations. The current guideline recommendations are based on limited data, and no data that is specific to cardiac arrest patients. There is a recognized need for research to better guide ventilation during CPR. This research will help to better define appropriate ventilation targets for cardiac arrest patients.",[513],"Cardiac Arrest",[515,516,517,518],"Resuscitation","Ventilation","Cardiopulmonary Resuscitation","Out-of-Hospital Cardiac Arrest","2026-03-15",{"date":521,"type":34},"2026-03-18",{"date":523,"type":21},"2026-03",{"date":525,"type":21},"2028-03",{"name":40,"class":41},{"id":528,"slug":529,"hasResults":12,"nctId":530,"briefTitle":531,"officialTitle":532,"acronym":533,"eligibilityCriteria":534,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":535,"targetDuration":4,"studyType":22,"phases":536,"briefSummary":537,"conditions":538,"keywords":543,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":544,"lastUpdatePostDateStruct":545,"startDateStruct":547,"completionDateStruct":548,"leadSponsor":550,"locationsCount":4},"100629748","early-detection-of-metastatic-recurrence-among-patients-with-stage-ii-or-iii-triple-negative-breast-cancer-using-liquid-biopsy-and-imaging-100629748","NCT07478705","Early Detection of Metastatic Recurrence Among Patients With Stage II or III Triple Negative Breast Cancer Using Liquid Biopsy and Imaging","Early Detection of Metastatic Recurrence Among Patients With Stage II or III Triple Negative Breast Cancer (TNBC) Using Liquid Biopsy and Imaging: A Multi-Center Pilot Randomized Trial (EINSTEIN-TNBC)","EINSTEIN-TNBC","Inclusion Criteria:\n\n* Men or women aged 18 and over\n* Biopsy proven invasive triple negative breast cancer (defined here as estrogen receptor \\\u003C10%, progesterone receptor \\\u003C10%, human epidermal growth factor receptor 2 (HER2) negative status, with HER2 status being defined as per ASCO\u002FCAP guidelines)\n* T2-4\u002FN0 (\\>2 cm primary breast cancer as assessed clinically or on imaging in the absence of nodal involvement) OR T1c-4\u002FN1-3 disease (\\>10mm with fine needle aspirate or core biopsy confirming nodal involvement is required)\n* Residual disease (RCB 2 or 3) on surgical specimen after completion of neoadjuvant chemo(-immuno)therapy\n\nExclusion Criteria:\n\n* Inability to provide informed consent. Participants who require translators are allowed to enroll\n* Prior history of invasive breast cancer -Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the detection of BC recurrence on a liquid biopsy (patients with a history of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and carcinoma-in-situ of cervix are permitted to participate)-\n* Pregnant patients are not permitted\n* Creatinine clearance \\\u003C45 mL\u002Fmin using the Cockcroft-Gault equation.",{"count":144,"type":21},[24],"Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer, often with poor outcomes. Currently, follow-up for TNBC consists of physical exams and annual breast imaging, with additional scans only if symptoms appear. This approach may delay the detection of the cancer coming back until the disease is advanced.\n\nA promising new technique is the detection of circulating tumor DNA (ctDNA)-in the blood. Studies suggest ctDNA may identify cancer recurrence months before it becomes visible on scans or causes symptoms. However, it is unknown whether detecting recurrence earlier can actually help patients live longer or feel better.\n\nThe EINSTEIN-TNBC trial is a study aiming to evaluate the feasibility of ctDNA-guided surveillance for patients with TNBC after surgery.\n\nThirty participants will be randomized to either:\n\nStandard of care (routine physical exams and annual breast imaging), or Active surveillance (standard of care plus ctDNA testing, with imaging investigations if ctDNA is detected).\n\nThis study will assess the feasibility of conducting a ctDNA-based monitoring trial in this patient population.\n\nIf feasible, EINSTEIN-TNBC will lay the foundation for a larger future clinical trial to determine whether earlier detection of metastatic TNBC can improve survival and quality of life.",[539,540,541,542],"Triple Negative Breast Cancer","Surveillance","Recurrence","ctDNA",[542,539,540,541],"2026-03-13",{"date":546,"type":34},"2026-03-17",{"date":106,"type":21},{"date":549,"type":21},"2029-05-01",{"name":40,"class":41},{"id":552,"slug":553,"hasResults":12,"nctId":554,"briefTitle":555,"officialTitle":555,"acronym":556,"eligibilityCriteria":557,"healthyVolunteers":12,"sex":17,"minAge":558,"maxAge":4,"enrollmentInfo":559,"targetDuration":4,"studyType":22,"phases":561,"briefSummary":562,"conditions":563,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":565,"lastUpdatePostDateStruct":566,"startDateStruct":567,"completionDateStruct":569,"leadSponsor":571,"locationsCount":42},"100629601","phase-2-daily-temozolomide-for-elderly-patients-with-unmethylated-mgmt--promoter-newly-diagnosed-glioblatoma-100629601","NCT07476794","Daily Temozolomide for Elderly Patients With Unmethylated MGMT- Promoter Newly Diagnosed GliOblatoma","TEMPO","Inclusion Criteria:\n\n* Age ≥65 years.\n* Histopathologically confirmed newly diagnosed WHO grade 4, IDH wild-type GBM\n* Unmethylated MGMT promoter, according to local assessment\n* Completed treatment with 40 Gy in 15 fractions over three weeks, with concurrent TMZ, within six weeks prior to enrollment\n* Eastern Cooperative Oncology Group (ECOG) performance status scale of 0, 1, or 2.\n* Karnofsky Performance Status (KPS) ≥60.\n* Adequate organ function, as defined by the following laboratory values obtained within 28 days prior to enrollment:\n\n  * Absolute neutrophil count (ANC) \\>1.5 × 10⁹\u002FL (1,500 cells\u002Fmm³).\n  * Platelet count \\>100 × 10⁹\u002FL (100,000 cells\u002Fmm³).\n  * Serum creatinine \\\u003C1.5 times the upper limit of normal.\n  * Total serum bilirubin \\\u003C1.5 times the upper limit of normal.\n  * ALT (SGPT) \\\u003C2.5 times the upper limit of normal and\u002For AST (SGOT) \\\u003C2.5 times the upper limit of normal.\n* Signed informed consent (and assent, if applicable) must be obtained from the participant or their legal representative, ensuring the participant's ability to adhere to the study requirements.\n\nExclusion Criteria:\n\n* Diffuse leptomeningeal involvement at the time of diagnosis.\n* Inability to undergo contrast-enhanced magnetic resonance imaging (MRI)\n* Known hypersensitivity to TMZ components or Dacarbazine\n* Severe myelosuppression\n* Active hepatitis B infection\n* Severe or uncontrolled medical conditions (e.g., active systemic infection, diabetes, hypertension, coronary artery disease, or psychiatric disorders) that, in the investigator's judgment, could compromise patient safety or impede study completion.\n* History of prior or second invasive malignancy, except for:\n\n  * Non-melanoma skin cancer.\n  * Completely resected cervical carcinoma in situ.\n  * Low risk prostate cancer or under active surveillance.\n  * Other cancers for which the subject has completed potentially curative treatment more than 3 years prior to study entry are allowed.","65 Years",{"count":560,"type":21},118,[313],"Glioblastoma is an aggressive type of brain cancer. Standard treatment usually includes three weeks of radiation therapy alone or combined with chemotherapy using Temozolomide. After a four- to six-week break, more Temozolomide chemotherapy is usually given. However, some tumors have a marker (\"unmethylated MGMT\") that predicts the usual chemotherapy won't work. Because of this, this project will explore other treatment options to help slow the disease and improve survival. In this study, the same chemotherapy (Temozolomide) normally given after radiation therapy for glioblastoma. The only difference is that it will be given with a modified regimen.",[564],"Glioblastoma","2026-03-12",{"date":546,"type":34},{"date":568,"type":34},"2025-11-01",{"date":570,"type":21},"2029-11",{"name":40,"class":41},{"id":573,"slug":574,"hasResults":12,"nctId":575,"briefTitle":576,"officialTitle":577,"acronym":578,"eligibilityCriteria":579,"healthyVolunteers":12,"sex":17,"minAge":580,"maxAge":581,"enrollmentInfo":582,"targetDuration":4,"studyType":22,"phases":584,"briefSummary":585,"conditions":586,"keywords":589,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":565,"lastUpdatePostDateStruct":600,"startDateStruct":601,"completionDateStruct":603,"leadSponsor":605,"locationsCount":229},"100629650","phase-2-levetiracetam-for-persons-at-risk-for-alzheimers-disease-100629650","NCT07477431","Levetiracetam for Persons at Risk for Alzheimer's Disease","A Proof-of-Concept, Multicentre, Phase IIb, Randomized Double-Blind Crossover Trial of Levetiracetam vs Placebo for Hippocampal Hyperactivity in Cognitively Normal Individuals at Risk for Alzheimer's Disease","ALEVIATE-2","Inclusion Criteria:\n\n* Willing to undergo all study procedures and has signed the informed consent form.\n* Has a friend or family member who has weekly contact with the participant and is willing to sign the study partner informed consent and complete study questionnaires.\n* Female participants must be post-menopausal (amenorrheic for at least 12 consecutive months without other known or suspected cause) or surgically sterile (bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy).\n* Sufficiently fluent in English to undergo cognitive testing, per investigator judgment.\n* Presence of subjective cognitive complaints, indicated by score \\>7 on MyCog portion of the Subjective Cognitive Decline Questionnaire (SCD-Q) at Screening.\n* Family history of Alzheimer's disease or of dementia suggestive of possible or probable Alzheimer's disease in a first-degree relative.\n* Head circumference \\\u003C60cm.\n* Within normal limits on all domains of the Toronto Cognitive Assessment (TorCA) at Screening or in the previous 6 months, with the exceptions noted below:\n\n  1. A borderline score on the executive domain may be acceptable if in the opinion of the investigator it is solely attributable to the participant having ADHD.\n  2. A borderline score on the language domain may be acceptable if in the opinion of the investigator it is solely attributable to English not being the participant's primary language.\n* Known to be within normal limits on the Montreal Cognitive Assessment (MoCA), Cogniciti Brain Health Assessment (BHA), or Toronto Cognitive Assessment (TorCA) in the previous 6 months, or within normal limits on the MoCA at Screening.\n* Hippocampal hyperactivation, defined as activation \\>1.5 SD above the mean, during the pattern separation task (PST) on BOLD fMRI.\n\nExclusion Criteria:\n\n* History of hypersensitivity to levetiracetam or any other ingredients in the study drug or placebo.\n* Significant neurological disease, including but not limited to:\n\n  1. Any type of cognitive impairment\n  2. History of transient ischemic attacks within 12 months of Screening\n  3. History of seizures within 12 months of Screening\n  4. Epilepsy\n  5. Parkinson's disease\n  6. Stroke (aside from subcortical lacunar infarcts)\n  7. Multiple sclerosis\n  8. Huntington's disease\n  9. Normal pressure hydrocephalus\n  10. Brain tumour (aside from benign tumours without mass effect, which are to be judged on a case-by-case basis)\n  11. Subdural hematoma\n  12. History of traumatic brain injury with persistent neurological deficits\n  13. Known structural brain abnormalities\n* Significant or unstable psychiatric disease, including but not limited to:\n\n  1. Schizophrenia\n  2. Bipolar disorder\n  3. Major depression which is not controlled in the opinion of the investigator\n  4. Score ≥10 on the Geriatric Depression Scale (GDS) at Screening\n  5. Presence of active suicidal ideation within the last 3 months as indicated by \"yes\" response to Question 4 or 5 on the Suicidal Ideation portion of the C-SSRS at Screening\n  6. Answered \"yes\" to any of the suicide-related behaviours within the last 3 months on the Suicidal Behavior portion of the C-SSRS\n  7. Hospitalized or treated for suicidal behavior within 5 years of Screening\n  8. Psychotic features, agitation, or behavioral problems within the last 3 months that could lead to difficulty complying with the protocol in the opinion of the investigator\n  9. Score ≥9 on the Mild Behavioural Impairment Checklist (MBI-C) at Screening\n* Known or suspected history of drug or alcohol abuse or dependence within 2 years before Screening).\n* Significant or unstable systemic illness or medical condition that would in the investigator's judgment make the participant unsuitable for inclusion in the study, including but not limited to:\n\n  1. History of malignancy within 3 years of screening (except of basal or squamous cell carcinoma of the skin)\n  2. Moderate-severe chronic kidney disease, chronic obstructive pulmonary disease, or congestive heart failure\n* Any of the following findings on a current (completed during screening) or previous brain MRI\u002FCT scan:\n\n  1. Severe white matter disease (Fazekas score66 = 3)\n  2. Stroke involving a major vascular territory\n  3. Subcortical lacunar infarcts \\>1.5cm in diameter\n  4. Encephalomalacia\n  5. Vascular malformations that are at high risk of hemorrhage\n  6. Infective lesions\n  7. Space-occupying lesions\n  8. Any other abnormality that would in the opinion of the investigator make the participant unsuitable for participation in the study\n* Any contraindications to MRI or MEG (e.g., pacemaker, ferromagnetic metal implants, claustrophobia).\n* Treatment with the following medications at time of screening or while in the study:\n\n  1. Anticonvulsant medications\n  2. Methotrexate\n  3. Anticholinergic agents and medications with anticholinergic properties\n* Creatinine clearance \\\u003C50ml\u002Fmin\u002F1.73m2 on screening bloodwork.\n* QTc interval \\>470 msec (males) or \\>480 msec (females) on screening ECG.\n* Clinically significant abnormal results on screening bloodwork that would in the opinion of the investigator make the participant unsuitable for inclusion in the study.","55 Years","85 Years",{"count":583,"type":21},40,[313],"The goal of this clinical trial is to investigate whether very small doses of a drug called levetiracetam (LEV) may reduce abnormal brain signaling in individuals who are at an increased risk for developing Alzheimer's Disease (AD). The study is looking for individuals who have a parent or sibling with Alzheimer's disease (dementia), and who have memory complaints but are currently performing within normal limits on cognitive testing. During the screening period, a functional MRI (fMRI) scan of the brain will identify those participants who have the abnormal brain signaling that the study is looking to treat.\n\nAll participants will receive 4 weeks of treatment with LEV and 4 weeks of treatment with placebo (a sugar pill), but it will not be known what order they will receive them in. Participants will undergo cognitive testing, genetic testing, and several brain imaging scans as part of the study.\n\nThis is a pilot study, meaning that it is being carried out for the first time in a small number of participants. If the results show that treatment with LEV appears to be more beneficial than placebo in normalizing brain signaling, a larger study may follow.\n\nThis study is only being carried out in Toronto, Canada.",[587,588],"Hippocampal Hyperactivation","Prodromal Alzheimer Disease",[590,591,592,593,594,595,596,597,598,599,319],"EEG-MEG","fMRI","Pattern Separation Task","PST","Levetiracetam","Crossover Design","AD","Prodromal AD","Hippocampal hyperactivation","Subjective cognitive complaints",{"date":546,"type":34},{"date":602,"type":34},"2025-10-23",{"date":604,"type":21},"2027-02",{"name":40,"class":41},{"id":607,"slug":608,"hasResults":12,"nctId":609,"briefTitle":610,"officialTitle":611,"acronym":612,"eligibilityCriteria":613,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":614,"targetDuration":4,"studyType":22,"phases":616,"briefSummary":617,"conditions":618,"keywords":620,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":565,"lastUpdatePostDateStruct":624,"startDateStruct":625,"completionDateStruct":626,"leadSponsor":628,"locationsCount":42},"100629716","phase-2-a-phase-ii-trial-evaluating-radiation-boost-to-painful-spinal-metastases-100629716","NCT07478289","A Phase II Trial Evaluating Radiation Boost to Painful Spinal Metastases","OPTimized Dose Escalation With Simultaneous Integrated Boost for High Risk Spinal Metastases: a Prospective Phase II TriAL (OPTIMAL)","OPTIMAL","Inclusion Criteria:\n\n* Histopathologically confirmed solid tumor malignancy, or strong suspicion based on clinical and radiographic examination of malignancy\n* Spinal metastases with paraspinal disease extension documented with MRI and recommended for treatment with SBRT\n* Post-operative SBRT is permitted (after stabilization and\u002For decompression surgery) as long as no prior radiotherapy had been delivered to the spinal level planned for trial treatment and paraspinal disease is present\n* ECOG performance status 0-2\n* Able to tolerate protocol SBRT\n* Age 18 years or older\n* Patient is able and willing to complete the Patient Diary (pain and analgesic use)\n* Consent must be appropriately obtained in accordance with local requirements. Each patient must sign a consent form prior to enrollment in the trial to document their willingness to participate\n* Patients must be accessible for treatment and follow-up\n* Treatment to begin within 14 days (ideally 7 days) of radiotherapy simulation\n\nExclusion Criteria:\n\n* Extremely radiosensitive histology (seminoma, small cell lung cancer, hematologic primaries)\n* Prior radiotherapy in the spine target of interest\n* Spinal instability as assessed by the Spinal Instability Neoplastic Score with a score of \\> 12\n* Symptomatic cord compression or cauda equine syndrome resulting from bony compression or epidural compression of the spinal cord and cauda equina, respectively. Symptomatic refers to neurologic deficit in the form of motor, bowel or bladder dysfunction\n* Pacemaker, such that MRI cannot be performed or treatment cannot be delivered safely\n* Cytotoxic chemotherapy within 1 week prior to radiotherapy delivery",{"count":615,"type":21},108,[313],"Spine SBRT is considered a standard of care for the treatment of spinal metastases. Compared to conventional radiation therapy, spine SBRT delivers high doses of radiation to the affected areas to the spinal metastases.\n\nThis study is interested in seeing whether an additional 'boost' of radiation, delivered to the affected area in the spine, will result in better long-term control of the tumor; help reduce pain; and reduce long-term side effects of radiation therapy.",[619],"Spine Metastasis",[621,622,623],"spinal metastases","SBRT","Simultaneous Integrated Boost",{"date":546,"type":34},{"date":362,"type":21},{"date":627,"type":21},"2031-12",{"name":40,"class":41},{"id":630,"slug":631,"hasResults":12,"nctId":632,"briefTitle":633,"officialTitle":634,"acronym":635,"eligibilityCriteria":636,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":637,"targetDuration":4,"studyType":22,"phases":639,"briefSummary":641,"conditions":642,"keywords":644,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":565,"lastUpdatePostDateStruct":647,"startDateStruct":649,"completionDateStruct":650,"leadSponsor":651,"locationsCount":42},"100576161","phase-3-intravenous-ketamine-and-immersive-virtual-reality-to-treat-depression-100576161","NCT06781697","InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression","InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression (TREASURE Trial): a Pilot, Randomized Controlled Trial","TREASURE","Inclusion Criteria:\n\n* Age ≥ 18, able to provide informed consent\n* Patient diagnosed with treatment-resistant depression\n* Outpatient recommended and approved by psychiatrist for ketamine treatment\n* Patients who are on IV ketamine and requiring at least 4 treatments of IV ketamine per course (prescribed by their physiatrist)\n* Cognitively alert, oriented, and able to watch immersive content and respond to questions\n* Negative human chorionic gonadotropin test before treatment, for female participants of childbearing potential who are not practicing medically appropriate methods of birth control (e.g., hormonal contraceptives, implants, injectables, intrauterine devices, intrauterine systems, etc.)\n\nExclusion Criteria:\n\n* History of psychosis\u002Fcomorbid psychiatric disorders\u002Fpsychotic depression\u002Fdissociative syndromes, significant personality disorder, as clinically assessed by psychiatrist\n* Using non-prescribed substance (e.g., cannabis) or alcohol use within the preceding 48 hours of treatment\n* History of substance misuse and\u002For dependence, including chronic alcohol abuse\n* Previous ketamine use\n* Acute dementia\u002Fdelirium\n* Acute risk of suicide at baseline, as determined by the study psychiatrist\n* Pregnancy\u002Fbreastfeeding\n* Previous sensitivity to ketamine or related compounds\n* Unstable medical condition which may require anesthesia consult\n* History of elevated intracranial pressure or cerebrovascular accident\n* Recent (within 6 weeks) major cardiovascular event (such as myocardial infarction)\n* Significant motion sickness (i.e. occur during exposure to physical\u002Fvisual and virtual motion, cybersickness, etc.) self-identified by patient\n* Inability to communicate with the study team",{"count":638,"type":21},31,[640],"PHASE3","Depression is a common condition, with serious negative effects on the health and quality of life of those affected. While there are currently various medications which attempt to treat depression, they often take a long time to begin to work and do not work at all for many people. There is therefore a need for new treatments which work quickly and effectively.\n\nOne such medication is called ketamine. Studies have shown that ketamine can treat symptoms of depression quickly. This quick action sets ketamine apart from many antidepressants that take weeks to show noticeable effects. One way that it may do this is by creating a transient sense or feeling of being separated from reality, such as seeing or hearing things that are not really there. Another way to create these same feelings is with virtual reality (VR), where a person can feel as though they are entering a 3-dimensional virtual computer-generated world by wearing a special headset or goggles with a computer inside.\n\nIn this study, all participants will receive standard ketamine treatments for depression. Half of the participants will also use a VR headset while receiving the ketamine treatments to see if ketamine and VR acting together provide a better treatment for symptoms of depression than ketamine alone.\n\nThis is a small pilot trial. The main purpose of this trial is to learn if it is possible to run a larger clinical trial comparing \"ketamine and VR\" with \"ketamine alone\", for adults with treatment-resistant depression. The researchers will study this by seeing how many participants take part in the study within 1-2 years, and how many complete the study treatments and tests. The researchers will also compare the two study groups to see if \"ketamine and VR\" provide a better treatment for symptoms of depression than \"ketamine alone\".",[643],"Treatment Resistant Depression",[489,645,646,643],"Ketamine","Virtual Reality",{"date":648,"type":34},"2026-03-16",{"date":130,"type":21},{"date":389,"type":21},{"name":40,"class":41},""]